Healome Therapeutics (University of Birmingham spinout) closed an oversubscribed GBP£2 million seed financing round led by Empirical Ventures to develop an eye-drop matrix technology for ocular surface diseases. The successful, oversubscribed round is a modest positive for the company’s near-term funding outlook, but is unlikely to materially move public market prices.
Healome Therapeutics (University of Birmingham spinout) closed an oversubscribed GBP£2 million seed financing round led by Empirical Ventures to develop an eye-drop matrix technology for ocular surface diseases. The successful, oversubscribed round is a modest positive for the company’s near-term funding outlook, but is unlikely to materially move public market prices.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
